

Patient-derived Xenograft Model Market Forecasts to 2030 – Global Analysis By Model Type (Mice Models and Rat Models), Tumor Type (Gastrointestinal Tumors, Gynecological Tumors, Respiratory Tumors and Other Tumor Types), Implantation Method (Subcutaneous and Orthotopic), Application, End User and By Geography

<https://marketpublishers.com/r/P3375FF94B22EN.html>

Date: February 2025

Pages: 150

Price: US\$ 4,150.00 (Single User License)

ID: P3375FF94B22EN

Abstracts

According to Statistics MRC, the Global Patient-derived Xenograft Model Market is accounted for \$494.3 million in 2024 and is expected to reach \$1102.3 million by 2030 growing at a CAGR of 14.3% during the forecast period. An experimental system known as a patient-derived xenograft (PDX) model involves implanting tumor tissues from human patients into immunocompromised mice. This model is a useful tool for cancer research because it maintains the original tumor's genetic and phenotypic features. Compared to conventional cell line models, PDX models provide a more realistic depiction of human cancer and are utilized to investigate tumor biology, test therapeutic medications, and create personalized medicine strategies.

According to Dana-Farber Cancer Institute study, 16 out of 29 patients with advanced sarcoma successfully established PDX models.

Market Dynamics:

Driver:

Rising demand for personalized medicine

The rising demand for personalized medicine is driving the patient-derived xenograft (PDX) model market. PDX models enable researchers to study patient-specific cancer biology and drug responses, making them essential for tailoring treatments to individual genetic profiles. This approach improves therapeutic efficacy and reduces adverse effects, aligning with the growing focus on precision oncology. The increasing prevalence of cancer and advancements in genomics further amplify the need for personalized medicine.

Restraint:

High costs of development and maintenance

Establishing and sustaining PDX models require significant financial resources, specialized expertise, and advanced infrastructure. The complex processes involved in tumor implantation and maintenance limit accessibility for smaller research organizations. Additionally, the high cost of immunodeficient animals and human tumor samples further increases expenses. These financial barriers pose challenges to widespread adoption.

Opportunity:

Advancements in cancer research

Advancements in cancer research are creating opportunities for the PDX model market. Innovations such as CRISPR-based gene editing, AI-driven data analysis and humanized PDX models are enhancing the accuracy and efficiency of preclinical studies. These advancements allow researchers to explore novel therapeutic targets, improve biomarker discovery, and accelerate drug development processes. Additionally, increasing public and private investments in oncology research are driving demand for advanced PDX models.

Threat:

Ethical concerns and regulatory challenges

Ethical concerns and regulatory challenges threaten the growth of the PDX model market. The use of animals in research raises ethical issues, leading to stringent guidelines that can delay or restrict studies. Regulatory agencies like the FDA have introduced measures to reduce reliance on animal models, potentially affecting market

dynamics. These challenges necessitate compliance with complex protocols, increasing operational costs and timeframes for research organizations.

Covid-19 Impact:

The COVID-19 pandemic negatively impacted the PDX model market due to disruptions in laboratory operations, supply chains, and research funding. Many oncology studies were delayed as resources were diverted toward COVID-19 research. However, the pandemic underscored the importance of personalized medicine, highlighting the relevance of PDX models in cancer research. As restrictions eased, demand rebounded with renewed focus on innovative cancer therapies.

The mice models segment is expected to be the largest during the forecast period

The mice models segment is expected to account for the largest market share during the forecast period. Mice are widely used due to their genetic similarity to humans, ease of handling, and cost-effectiveness compared to other animals. They provide a robust platform for studying tumor growth, drug efficacy, and resistance mechanisms in vivo. The availability of well-established protocols for mice-based PDX models further supports their dominance in preclinical oncology research.

The biobanking segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biobanking segment is expected to witness the highest CAGR due to its role in preserving patient-derived tumor samples for future use. Biobanks enable researchers to access diverse tumor specimens for developing new PDX models and conducting retrospective studies. This capability accelerates drug discovery processes while ensuring reproducibility in experiments. The growing emphasis on personalized medicine drives demand for biobanking services as an essential component of preclinical research infrastructure.

Region with largest share:

The North America region is anticipated to account for the largest market share during the forecast period. Factors such as a high prevalence of cancer, advanced healthcare infrastructure, and significant public-private investments in oncology research drive regional growth. The presence of key industry players further strengthens North America's position as a leader in PDX model adoption. Additionally, government

initiatives supporting precision medicine also contribute significantly to this dominance.

Region with highest CAGR:

The Asia Pacific region is anticipated to register the highest growth rate over the forecast period. Rapid urbanization, increasing healthcare expenditure, and rising cancer incidence drive demand for advanced research tools like PDX models in this region. The shift toward modern healthcare practices positions Asia Pacific as a key growth hub. Furthermore, countries like China and India are investing heavily in biotechnology and pharmaceutical R&D, fostering market expansion.

Key players in the market

Some of the key players in Patient-derived Xenograft Model Market include Champions Oncology, Charles River Laboratories, Crown Bioscience, EPO Berlin-Buch, Hera BioLabs, Horizon Discovery Group, Inotiv, JSR Corporation, Oncodesign Precision Medicine, Pharmatest Services, Taconic Biosciences, The Jackson Laboratory, Urolead, WuXi AppTec, Xenopat and Xentech.

Key Developments:

In December 2024, Can-Fite BioPharma Ltd. recently announced that its work titled The Liver Protective Effect of the Anti-Cancer Drug Candidate Namodenoson is mediated via Adiponectin will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium to take place at San Francisco & On Line, January 23-25.

In October 2019, Crown Bioscience announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity and speed of preclinical drug discovery. The initial phase of the platform launch features the first commercially available 3D in vitro PDX-derived organoid (PDXO) models generated from CrownBio's uniquely-characterized library of 2500+ patient-derived xenograft (PDX) models.

In May 2015, Taconic Biosciences and Cellaria Biosciences have entered into a scientific collaboration designed to improve the utility of patient-derived xenografts (PDXs) in animal models for oncology and immuno-oncology research. Cellaria's novel methodologies for generating cells from patient tumors will complement Taconic's industry-leading portfolio of tissue humanized mouse models, which are said to be well suited as hosts for PDXs.

Model Types Covered:

Mice Models

Rat Models

Tumor Types Covered:

Gastrointestinal Tumors

Gynecological Tumors

Respiratory Tumors

Breast Cancer Tumors

Hematological Tumors

Urological Tumors

Neurological Tumors

Other Tumor Types

Implantation Methods Covered:

Subcutaneous

Orthotopic

Applications Covered:

Preclinical Drug Development

Biomarker Analysis

Biobanking

Translational Research

End Users Covered:

Pharmaceutical & Biotechnology Companies

Academic & Research Institutions

Contract Research Organizations

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY MODEL TYPE

- 5.1 Introduction
- 5.2 Mice Models
 - 5.2.1 NOD SCID Models
 - 5.2.2 NSG Models
 - 5.2.3 Other Immunodeficient Models
- 5.3 Rat Models
 - 5.3.1 Immunodeficient Rat Models
 - 5.3.2 Humanized Rat Models

6 GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY TUMOR TYPE

- 6.1 Introduction
- 6.2 Gastrointestinal Tumors
- 6.3 Gynecological Tumors
- 6.4 Respiratory Tumors
- 6.5 Breast Cancer Tumors
- 6.6 Hematological Tumors
- 6.7 Urological Tumors
- 6.8 Neurological Tumors
- 6.9 Other Tumor Types

7 GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY IMPLANTATION METHOD

- 7.1 Introduction
- 7.2 Subcutaneous
- 7.3 Orthotopic
 - 7.3.1 Surgical Implantation
 - 7.3.2 Non-surgical Implantation

8 GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY APPLICATION

- 8.1 Introduction
- 8.2 Preclinical Drug Development
- 8.3 Biomarker Analysis
- 8.4 Biobanking
- 8.5 Translational Research

9 GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY END USER

- 9.1 Introduction
- 9.2 Pharmaceutical & Biotechnology Companies
- 9.3 Academic & Research Institutions
- 9.4 Contract Research Organizations

10 GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY GEOGRAPHY

- 10.1 Introduction
- 10.2 North America
 - 10.2.1 US
 - 10.2.2 Canada
 - 10.2.3 Mexico
- 10.3 Europe
 - 10.3.1 Germany
 - 10.3.2 UK
 - 10.3.3 Italy
 - 10.3.4 France
 - 10.3.5 Spain
 - 10.3.6 Rest of Europe
- 10.4 Asia Pacific
 - 10.4.1 Japan
 - 10.4.2 China
 - 10.4.3 India
 - 10.4.4 Australia
 - 10.4.5 New Zealand
 - 10.4.6 South Korea
 - 10.4.7 Rest of Asia Pacific
- 10.5 South America
 - 10.5.1 Argentina
 - 10.5.2 Brazil
 - 10.5.3 Chile
 - 10.5.4 Rest of South America
- 10.6 Middle East & Africa
 - 10.6.1 Saudi Arabia
 - 10.6.2 UAE
 - 10.6.3 Qatar

10.6.4 South Africa

10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

11.1 Agreements, Partnerships, Collaborations and Joint Ventures

11.2 Acquisitions & Mergers

11.3 New Product Launch

11.4 Expansions

11.5 Other Key Strategies

12 COMPANY PROFILING

12.1 Champions Oncology

12.2 Charles River Laboratories

12.3 Crown Bioscience

12.4 EPO Berlin-Buch

12.5 Hera BioLabs

12.6 Horizon Discovery Group

12.7 Inotiv

12.8 JSR Corporation

12.9 Oncodesign Precision Medicine

12.10 Pharmatest Services

12.11 Taconic Biosciences

12.12 The Jackson Laboratory

12.13 Urolead

12.14 WuXi AppTec

12.15 Xenopat

12.16 Xentech

List Of Tables

LIST OF TABLES

- Table 1 Global Patient-derived Xenograft Model Market Outlook, By Region (2022-2030) (\$MN)
- Table 2 Global Patient-derived Xenograft Model Market Outlook, By Model Type (2022-2030) (\$MN)
- Table 3 Global Patient-derived Xenograft Model Market Outlook, By Mice Models (2022-2030) (\$MN)
- Table 4 Global Patient-derived Xenograft Model Market Outlook, By NOD SCID Models (2022-2030) (\$MN)
- Table 5 Global Patient-derived Xenograft Model Market Outlook, By NSG Models (2022-2030) (\$MN)
- Table 6 Global Patient-derived Xenograft Model Market Outlook, By Other Immunodeficient Models (2022-2030) (\$MN)
- Table 7 Global Patient-derived Xenograft Model Market Outlook, By Rat Models (2022-2030) (\$MN)
- Table 8 Global Patient-derived Xenograft Model Market Outlook, By Immunodeficient Rat Models (2022-2030) (\$MN)
- Table 9 Global Patient-derived Xenograft Model Market Outlook, By Humanized Rat Models (2022-2030) (\$MN)
- Table 10 Global Patient-derived Xenograft Model Market Outlook, By Tumor Type (2022-2030) (\$MN)
- Table 11 Global Patient-derived Xenograft Model Market Outlook, By Gastrointestinal Tumors (2022-2030) (\$MN)
- Table 12 Global Patient-derived Xenograft Model Market Outlook, By Gynecological Tumors (2022-2030) (\$MN)
- Table 13 Global Patient-derived Xenograft Model Market Outlook, By Respiratory Tumors (2022-2030) (\$MN)
- Table 14 Global Patient-derived Xenograft Model Market Outlook, By Breast Cancer Tumors (2022-2030) (\$MN)
- Table 15 Global Patient-derived Xenograft Model Market Outlook, By Hematological Tumors (2022-2030) (\$MN)
- Table 16 Global Patient-derived Xenograft Model Market Outlook, By Urological Tumors (2022-2030) (\$MN)
- Table 17 Global Patient-derived Xenograft Model Market Outlook, By Neurological Tumors (2022-2030) (\$MN)
- Table 18 Global Patient-derived Xenograft Model Market Outlook, By Other Tumor

Types (2022-2030) (\$MN)

Table 19 Global Patient-derived Xenograft Model Market Outlook, By Implantation Method (2022-2030) (\$MN)

Table 20 Global Patient-derived Xenograft Model Market Outlook, By Subcutaneous (2022-2030) (\$MN)

Table 21 Global Patient-derived Xenograft Model Market Outlook, By Orthotopic (2022-2030) (\$MN)

Table 22 "Global Patient-derived Xenograft Model Market Outlook, By Surgical Implantation (2022-2030) (\$MN)

Table 23 Global Patient-derived Xenograft Model Market Outlook, By Non-surgical Implantation (2022-2030) (\$MN)

Table 24 Global Patient-derived Xenograft Model Market Outlook, By Application (2022-2030) (\$MN)

Table 25 Global Patient-derived Xenograft Model Market Outlook, By Preclinical Drug Development (2022-2030) (\$MN)

Table 26 Global Patient-derived Xenograft Model Market Outlook, By Biomarker Analysis (2022-2030) (\$MN)

Table 27 Global Patient-derived Xenograft Model Market Outlook, By Biobanking (2022-2030) (\$MN)

Table 28 Global Patient-derived Xenograft Model Market Outlook, By Translational Research (2022-2030) (\$MN)

Table 29 Global Patient-derived Xenograft Model Market Outlook, By End User (2022-2030) (\$MN)

Table 30 Global Patient-derived Xenograft Model Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) (\$MN)

Table 31 Global Patient-derived Xenograft Model Market Outlook, By Academic & Research Institutions (2022-2030) (\$MN)

Table 32 Global Patient-derived Xenograft Model Market Outlook, By Contract Research Organizations (2022-2030) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Patient-derived Xenograft Model Market Forecasts to 2030 – Global Analysis By Model Type (Mice Models and Rat Models), Tumor Type (Gastrointestinal Tumors, Gynecological Tumors, Respiratory Tumors and Other Tumor Types), Implantation Method (Subcutaneous and Orthotopic), Application, End User and By Geography

Product link: <https://marketpublishers.com/r/P3375FF94B22EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P3375FF94B22EN.html>